Oppenheimer Starts Pharvaris B.V. (PHVS) at Outperform

Go back to Oppenheimer Starts Pharvaris B.V. (PHVS) at Outperform

SVB Leerink Starts Pharvaris B.V. (PHVS) at Outperform

March 2, 2021 6:32 AM EST

SVB Leerink analyst Joseph Schwartz initiates coverage on Pharvaris B.V. (NASDAQ: PHVS) with a Outperform rating and a price target of $50.00.


For an analyst ratings summary and ratings history on Pharvaris B.V.... More

BofA Securities Starts Pharvaris B.V. (PHVS) at Neutral

March 2, 2021 6:02 AM EST

BofA Securities initiates coverage on Pharvaris B.V. (NASDAQ: PHVS) with a Neutral rating and a price target of $41.00.


For an analyst ratings summary and ratings history on Pharvaris B.V.... More

UPDATE: Morgan Stanley Starts Pharvaris B.V. (PHVS) at Overweight Noting $1B Peak Sales Potential

March 2, 2021 5:13 AM EST

(Updated - March 2, 2021 7:24 AM EST)

Morgan Stanley analyst Matthew Harrison initiates coverage on Pharvaris B.V. (NASDAQ: PHVS) with a Overweight rating noting that the company is developing a high efficacy oral treatment for the $2B+ HAE market supported by initial data from... More